Treatment of mitochondrial disorders

Current Treatment Options in Neurology

Volumn 16, Issue 6, 2014, Pages

  Avula, Sreenivas ^a   Parikh, Sumit ^a   Demarest, Scott ^b   Kurz, Jonathan ^b   Gropman, Andrea ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Arginine; Bezafibrate; Carnitine; Coenzyme Q10; Creatine; Cysteine; Dichloroacetate (DCA); Dimethylglycine (DMG); Energy metabolism; EPI 743; Gene therapy; Idebenone; Lipoic acid; Mitochondria; Mitochondrial disorders; N acetyl cysteine (NAC); POLG1; Resveratrol; Riboflavin; Thiamine; Treatment

Indexed keywords

ACETYLCYSTEINE; ACYL COENZYME A DEHYDROGENASE; ACYL COENZYME A DEHYDROGENASE 9; ALPHA TOCOPHEROL; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIOXIDANT; ANTIRETROVIRUS AGENT; ARGININE; ASCORBIC ACID; BEZAFIBRATE; CARNITINE; CREATINE; CYSTEINE; DICHLOROACETIC ACID; DIMETHYLGLYCINE; FOLINIC ACID; IDEBENONE; MENADIONE; METRONIDAZOLE; RIBOFLAVIN; THIAMINE; THIOCTIC ACID; UBIDECARENONE; UBIQUINOL; UBIQUINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VATIQUINONE; VITAMIN K GROUP; XENOBIOTIC AGENT;

ACIDEMIA; ANOREXIA; ANTIOXIDANT ACTIVITY; CARDIOTOXICITY; CENTRAL PONTINE MYELINOLYSIS; CEREBROVASCULAR ACCIDENT; COMPLEX I DEFICIENCY; COMPLEX III DEFICIENCY; DEGENERATIVE DISEASE; DIARRHEA; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EPILEPSY; EPILEPTIC STATE; EXERCISE; GASTROINTESTINAL SYMPTOM; GENE THERAPY; HEADACHE; HEARING IMPAIRMENT; HEART ARRHYTHMIA; HUMAN; HYPOGLYCEMIA; HYPONATREMIA; HYPOTENSION; INTENSIVE CARE; INTENSIVE CARE UNIT; INTRACTABLE EPILEPSY; IRON ABSORPTION; KETOGENIC DIET; KIDNEY FAILURE; LACTATE BLOOD LEVEL; LEBER HEREDITARY OPTIC NEUROPATHY; LEIGH DISEASE; LIVER DISEASE; LIVER DYSFUNCTION; MELAS SYNDROME; MYOPATHY; NAUSEA; NEPHROTOXICITY; PERIPHERAL NEUROPATHY; PHENOTYPE; PRURITUS; PYRUVATE DEHYDROGENASE COMPLEX DEFICIENCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESPIRATORY CHAIN; REVIEW; SIDE EFFECT; SLEEP DISORDER; WAKEFULNESS; WHEY;

EID: 84897355860     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-014-0292-7     Document Type: Review

References (97)

1. DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med. 2003;348:2656-68. (Pubitemid 36741594)
2. Parikh S, Saneto R, Falk MJ, et al. Modern Approach to the Treatment of Mitochondrial Disease. Curr Treat Options Neurol. 2009;11:414-30.
3. Glover EI, Martin J, Maher A, et al. A randomized trial of coenzyme Q10 in mitochondrial disorders. Muscle Nerve. 2010;42:739-48.
4. Esposti MD, Ngo A, Ghelli A, et al. The interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the respiratory complexes of heart mitochondria. Arch Biochem Biophys. 1996;330:395-400. (Pubitemid 26172376)
5. Gempel K, Topaloglu H, Talim B, et al. The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene. Brain. 2007;130:2037-44. (Pubitemid 47236610)
6. Mancuso M, Orsucci D, Filosto M, et al. Drugs and mitochondrial diseases: 40 queries and answers. Expert Opin Pharmacother. 2012;13(4):527-43.
7. Klopstock T, Yu-Wai-Man P, Dimitriadis K, et al. A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain. 2011;134(Pt 9):2677-86.
8. •• Rudolph G, Dimitriadis K, Büchner B, et al. Effects of idebenone on color vision in patients with leber hereditary optic neuropathy. J Neuroophthalmol. 2013;33(1):30-6. This randomized, double-blind placebo-controlled intervention demonstrated that idebenone can prevent loss of color vision, an early marker of LHON.
9. Garone C, Donati MA, Sacchini M, et al. Mitochondrial encephalomyopathy due to a novel mutation in ACAD9. JAMA Neurol. 2013;70(9):1177-9.
10. Haack TB, Danhauser K, Haberberger B, et al. Exome sequencing identifies ACAD9 mutations as a cause of complex I deficiency. Nat Genet. 2010;42(12):1131-4.
11. Abdelmalak M, Lew A, Ramezani R, et al. Long-term safety of dichloroacetate in congenital lactic acidosis. Mol Genet Metab. 2013;109(2):139-43.
12. Mermigkis C, Bouloukaki I, Mastorodemos V. Medical treatment with thiamine, coenzyme Q, vitamins E and C, and carnitine improved obstructive sleep apnea in an adult case of Leigh disease. Sleep Breath. 2013;17(4):1129-35.
13. Lands LC, Grey VL, Smountas AA. Effect of supplementation with a cysteine donor on muscular performance. J Appl Physiol. 1999;87:1381-5. (Pubitemid 29483123)
14. Mancuso M, Orsucci D, Logerfo A, et al. Oxidative stress biomarkers in mitochondrial myopathies, basally and after cysteine donor supplementation. J Neurol. 2010;257:774-81.
15. Tarnopolsky MA, Beal MF. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann Neurol. 2001;49:561-74. (Pubitemid 32429783)
16. Rodriguez MC, MacDonald JR, Mahoney DJ, et al. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve. 2007;35(2):235-42.
17. Marangon K, Devaraj S, Tirosh O, et al. Comparison of the effect of lipoic acid and tocopherol supplementation on measures of oxidative stress. Free Radic Biol Med. 1999;27:1114-21.
18. Nierenberg AA, Kansky C, Brennan BP, et al. Mitochondrial modulators for bipolar disorder. A pathophysiologically informed paradigm for new drug development. Aust N Z J Psychiatry. 2013;47:26-42.
19. Medved I, Brown MJ, Bjorksten AR, et al. N-acetylcysteine enhances muscle cysteine and glutathione availability and attenuates fatigue during prolonged exercise in endurance-trained individuals. J Appl Physiol. 2004;97:1477-85. (Pubitemid 39299368)
20. Mancuso M, Orsucci D, Logerfo A, et al. Oxidative stress biomarkers in mitochondrial myopathies, basally and after cysteine donor supplementation. J Neurol. 2010;257:774-81.
21. Reid MB, Stokic DS, Koch SM, et al. N-acetylcysteine inhibits muscle fatigue in humans. J Clin Investig. 1994;94:2468-74. (Pubitemid 24379623)
22. Viscomi C, Burlina AB, Dweikat I, et al. Combined treatment with oral metronidazole and N-acetylcysteine is effective in ethylmalonic encephalopathy. Nat Med. 2010;16:869-71.
23. El-Hattab AW, Hsu JW, Emrick LT, et al. Restoration of impaired nitric oxide production in MELAS syndrome with citrulline and arginine supplementation. Mol Genet Metab. 2012;105(4):607-14.
24. Siciliano G, Simoncini C, Lo Gerfo A, et al. Effects of aerobic training on exercise-related oxidative stress in mitochondrial myopathies. Neuromuscul Disord. 2012;3:S172-7.
25. Martinelli D, Catteruccia M, Piemonte F, et al. EPI-743 reverses the progression of the pediatric mitochondrial disease-genetically defined Leigh Syndrome. Mol Genet Metab. 2012;107(3):383-8.
26. Enns GM, Kinsman SL, Perlman SL, et al. Initial experience in the treatment of inherited mitochondrial disease with EPI-743. Mol Genet Metab. 2012;105(1):91-102.
27. Sadun AA, Chicani CF, Ross-Cisneros FN, et al. Effect of EPI 743 on the clinical course of the mitochondrial disease Leber hereditary optic neuropathy. Arch Neurol. 2012;69:331-8.
28. Komen JC, Thorburn DR. Turn up the power - pharmacological activation of mitochondrial biogenesis in mouse models. Br J Pharmacol. 2013. doi:10.1111/bph.12413.
29. •• Noe N, Dillon L, Lellek V, et al. Bezafibrate improves mitochondrial function in the CNS of a mouse model of mitochondrial encephalopathy. Mitochondrion. 2013;13(5):417-26. This randomized trial showed that bezafibrate had a neuroprotective effect in this mouse model of mitochondrial encephalopathy and suggest that bezafibrate might be a promising therapeutic agent for the treatment of neurodegenerative disease associated with mitochondrial dysfunction.
30. Chaturvedi RK, Beal MF. Mitochondrial approaches for neuroprotection. Ann N Y Acad Sci. 2008;1147:395-412.
31. Liet JM, Pelletier V, Robinson BH, et al. The effect of short-term dimethylglycine treatment on oxygen consumption in cytochrome oxidase deficiency: a double-blind randomized crossover clinical trial. J Pediatr. 2003;142(1):62-6. (Pubitemid 36106391)
32. Binzak BA, Wevers RA, Moolenaar SH, et al. Cloning of dimethylglycine dehydrogenase and a new human inborn error of metabolism, dimethylglycine dehydrogenase deficiency. Am J Hum Genet. 2001;68:839-47. (Pubitemid 32289729)
33. DiMauro S, Mancuso M. Mitochondrial diseases: therapeutic approaches. Biosci Rep. 2007;27:125-37. (Pubitemid 46940941)
34. Tachibana M, Sparman M, Sritanaudomchai H, et al. Mitochondrial gene replacement in primate offspring and embryonic stem cells. Nature. 2009;461:367-72.
35. Mah CS, Soustek MS, Todd AG, et al. Adeno-associated virus-mediated gene therapy for metabolic myopathy. Hum Gene Ther. 2013;24(11):928-36.
36. Kann O, Kovács R. Mitochondria and neuronal activity. Am J Physiol Cell Physiol. 2007;292(2):C641-57.
37. Kilbride SM, Telford JE, Tipton KF, Davey GP. Partial inhibition of complex I activity increases Ca-independent glutamate release rates from depolarized synaptosomes. J Neurochem. 2008;106(2):826-34.
38. Kunz WS. The role of mitochondria in epileptogenesis. Curr Opin Neurol. 2002;15(2):179-84. (Pubitemid 34286903)
39. McKenna MC. The glutamate-glutamine cycle is not stoichiometric: fates of glutamate in brain. J Neurosci Res. 2007;85(15):3347-58. (Pubitemid 350058523)
40. Molinari F, Kaminska A, Fiermonte G, Boddaert N. Mutations in the mitochondrial glutamate carrier SLC25A22 in neonatal epileptic encephalopathy with suppression bursts. Clin Genet. 2009;76(2):188-94.
41. Tzoulis C, Neckelmann G, Mørk SJ, et al. Localized cerebral energy failure in DNA polymerase gamma-associated encephalopathy syndromes. Brain. 2010;133(Pt 5):1428-37.
42. Lee YM, Kang HC, Lee JS, et al. Mitochondrial respiratory chain defects: underlying etiology in various epileptic conditions. Epilepsia. 2008;49(4):685-90. (Pubitemid 351661064)
43. Elliott HR, Samuels DC, Eden JA, et al. Pathogenic mitochondrial DNA mutations are common in the general population. Am J Hum Genet. 2008;83(2):254-60.
44. Uusimaa J, Hinttala R, Rantala H, et al. Homozygous W748S mutation in the POLG1 gene in patients with juvenile-onset Alpers syndrome and status epilepticus. Epilepsia. 2008;49(6):1038-45. (Pubitemid 351794000)
45. Pronicka E, Weglewska-Jurkiewicz A, et al. Drug-resistant epilepsia and fulminant valproate liver toxicity. Alpers-Huttenlocher syndrome in two children confirmed post mortem by identification of p.W748S mutation in POLG gene. Med Sci Monit. 2011;17(4):CR203-9.
46. Saneto RP, Lee IC, Koenig MK, et al. POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. Seizure. 2010;19(3):140-6.
47. Lin CM, Thajeb P. Valproic acid aggravates epilepsy due to MELAS in a patient with an A3243G mutation of mitochondrial DNA. Metab Brain Dis. 2007;22(1):105-9. (Pubitemid 46354826)
48. Lam CW, Lau CH, Williams JC, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. Eur J Pediatr. 1997;156(7):562-4. (Pubitemid 27289858)
49. Galimberti CA, Diegoli M, Sartori I, et al. Brain pseudoatrophy and mental regression on valproate and a mitochondrial DNA mutation. Neurology. 2006;67(9):1715-7. (Pubitemid 44747961)
50. Chaudhry N, Patidar Y, Puri V. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes unveiled by valproate. J Pediatr Neurosci. 2013;8(2):135-7.
51. Kaufman KR, Zuber N, Rueda-Lara MA, Tobia A. MELAS with recurrent complex partial seizures, nonconvulsive status epilepticus, psychosis, and behavioral disturbances: case analysis with literature review. Epilepsy Behav. 2010;18(4):494-7.
52. Bindoff LA, Engelsen BA. Mitochondrial diseases and epilepsy. Epilepsia. 2012;53 Suppl 4:92-7.
53. Corda D, Rosati G, Deiana GA, Sechi G. "Erratic" complex partial status epilepticus as a presenting feature of MELAS. Epilepsy Behav. 2006;8(3):655-8.
54. Chiyonobu T, Noda R, Yoshida M, et al. Intestinal pseudo-obstruction in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) associated with phenytoin therapy. Brain Dev. 2008;30(6):430-3.
55. Berger I, Segal I, Shmueli D, Saada A. The effect of antiepileptic drugs on mitochondrial activity: a pilot study. J Child Neurol. 2010;25(5):541-5.
56. Arpin S, Lagrue E, Bodard S, et al. Basal ganglia neuroprotection with anticonvulsants after energy stress: a comparative study. Metab Brain Dis. 2009;24(3):453-61.
57. Mancuso M, Galli R, Pizzanelli C, et al. Antimyoclonic effect of levetiracetam in MERRF syndrome. J Neurol Sci. 2006;243(1-2):97-9.
58. Rahman S. Mitochondrial disease and epilepsy. Dev Med Child Neurol. 2012;54(5):397-406.
59. Martikainen MH, Päivärinta M, Jääskeläinen S, Majamaa K. Successful treatment of POLG-related mitochondrial epilepsy with antiepileptic drugs and low glycaemic index diet. Epileptic Disord. 2012;14(4):438-41.
60. Joshi CN, Greenberg CR, Mhanni AA, Salman MS. Ketogenic diet in Alpers-Huttenlocher syndrome. Pediatr Neurol. 2009;40(4):314-6.
61. El Sabbagh S, Lebre AS, Bahi-Buisson N. Epileptic phenotypes in children with respiratory chain disorders. Epilepsia. 2010;51(7):1225-35.
62. Kang HC, Lee YM, Kim HD, et al. Safe and effective use of the ketogenic diet in children with epilepsy and mitochondrial respiratory chain complex defects. Epilepsia. 2007;48(1):82-8. (Pubitemid 46096027)
63. Pineda M, Ormazabal A, López-Gallardo E, et al. Cerebral folate deficiency and leukoencephalopathy caused by a mitochondrial DNA deletion. Ann Neurol. 2006;59(2):394-8. (Pubitemid 43202497)
64. Prüss H, Holtkamp M. Ketamine successfully terminates malignant status epilepticus. Epilepsy Res. 2008;82(2-3):219-22.
65. Koga Y, Povalko N, Katayama K, et al. Beneficial effect of pyruvate therapy on Leigh syndrome due to a novel mutation in PDH E1alpha gene. Brain Dev. 2012;34(2):87-91.
66. Ribacoba R, Salas-Puig J, González C, Astudillo A. Characteristics of status epilepticus in MELAS. Analysis of four cases. Neurologia. 2006;21(1):1-11.
67. Pfeffer G, Horvath R, Klopstock T, et al. New treatments for mitochondrial disease-no time to drop our standards. Nat Rev Neurol. 2013;9(8):474-81.
68. Gurrieri C, Kivela JE, Bojanić K, et al. Anesthetic considerations in mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes syndrome: a case series. Can J Anaesth. 2011;58:751-63.
69. Kubota H, Tanabe Y, Takanashi JI, Kohno Y. Episodic hyponatremia in mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes (MELAS). J Child Neurol. 2005;20:116-20. (Pubitemid 40484850)
70. Roberts NK, Perloff JK, Kark RA. Cardiac conduction in the Kearns-Sayre syndrome (a neuromuscular disorder associated with progressive external ophthalmoplegia and pigmentary retinopathy). Report of 2 cases and review of 17 published cases. Am J Cardiol. 1979;44:1396-400.
71. Sproule DM, Kaufmann P, Engelstad K, et al. Wolff-Parkinson-White syndrome in patients with MELAS. Arch Neurol. 2007;64:1625-7. (Pubitemid 350106764)
72. Muravchick S, Levy RJ. Clinical implications of mitochondrial dysfunction. Anesthesiology. 2006;105:819-37. (Pubitemid 44477329)
73. Thompson VA, Wahr JA. Anesthetic considerations in patients presenting with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome. Anesth Analg. 1997;85:1404-6. (Pubitemid 28130548)
74. Sasano N, Fujita Y, So M, Sobue K, Sasano H, Katsuya H. Anesthetic management of a patient with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) during laparotomy. J Anesth. 2007;21:72-5. (Pubitemid 46487044)
75. Wallace JJ, Perndt H, Skinner M. Anaesthesia and mitochondrial disease. Paediatr Anaesth. 1998;8:249-54. (Pubitemid 28242276)
76. Morgan PG, Hoppel CL, Sedensky MM. Mitochondrial defects and anesthetic sensitivity. Anesthesiology. 2002;96:1268-70. (Pubitemid 34462594)
77. James RH. Induction agent sensitivity and ophthalmoplegia plus. Anaesthesia. 1986;41:216. (Pubitemid 16133189)
78. Driessen J, Willems S, Dercksen S, et al. Anesthesia-related morbidity and mortality after surgery for muscle biopsy in children with mitochondrial defects. Paediatr Anaesth. 2007;17:16-21. (Pubitemid 44924372)
79. Wisely NA, Cook PR. General anaesthesia in a man with mitochondrial myopathy undergoing eye surgery. Eur J Anaesthesiol. 2001;18:333-5. (Pubitemid 32417800)
80. Naguib M, el Dawlatly AA, Ashour M, Al-Bunyan M. Sensitivity to mivacurium in a patient with mitochondrial myopathy. Anesthesiology. 1996;84:1506-9. (Pubitemid 26192061)
81. Finsterer J, Stratil U, Bittner R, Sporn P. Increased sensitivity to rocuronium and atracurium in mitochondrial myopathy. Can J Anaesth. 1998;45:781-4. (Pubitemid 28550513)
82. D'Ambra MN, Dedrick D, Savarese JJ. Kearns-Sayer syndrome and pancuronium-succinylcholine-induced neuromuscular blockade. Anesthesiology. 1979;51:343-5. (Pubitemid 10246040)
83. Kelly A, O'Connor M. Mitochondrial myopathy and anaesthesia. Anaesthesia. 1990;45:596.
84. Aouad M, Gerges F, Baraka A. Resistance to cisatracurium in a patient with MELAS syndrome. Paediatr Anaesth. 2005;15:1124-7. (Pubitemid 43965395)
85. Singer M. The role of mitochondrial dysfunction in sepsis-induced multi-organ failure. Virulence. 2014;5(1):66-72.
86. Ruggieri AJ, Levy RJ, Deutschman CS. Mitochondrial Dysfunction and Resuscitation in Sepsis. Crit Care Clin. 2010;26:567-75.
87. Cheng G, Kong RH, Zhang LM, Zhang JN. Mitochondria in traumatic brain injury and mitochondrial-targeted multipotential therapeutic strategies. Br J Pharmacol. 2012;167:699-719.
88. Kozlov AV, Bahrami S, Calzia E, et al. Mitochondrial dysfunction and biogenesis: do ICU patients die from mitochondrial failure? Ann Intensive Care. 2011;1:41.
89. Crouser ED. Autophagy, the First Step towards Recovery from Critical Illness*. Crit Care Med. 2013;41:358-9.
90. Carré JE, Orban JC, Re L, et al. Survival in Critical Illness Is Associated with Early Activation of Mitochondrial Biogenesis. Am J Respir Crit Care Med. 2010;182:745-51.
91. Kane JM, Rossi J, Tsao S, Burton BK. Metabolic Cardiomyopathy and Mitochondrial Disorders in the Pediatric Intensive Care Unit. J Pediatr. 2007;151:538-41.
92. Schreiber JM, Zelleke T, Gaillard WD, et al. Continuous Video EEG for Patients with Acute Encephalopathy in a Pediatric Intensive Care Unit. Neurocrit Care. 2012;17:31-8.
93. Towne AR, Waterhouse EJ, Boggs JG, et al. Prevalence of nonconvulsive status epilepticus in comatose patients. Am Acad Neurol. 2000;54:340-5. (Pubitemid 30078063)
94. Silva MFB, Aires CCP, Luis PBM, et al. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis. 2008;31:205-16.
95. Koga Y, Ishibashi M, Ueki I, et al. Effects of L-arginine on the acute phase of strokes in three patients with MELAS. Neurology. 2002;58:827-8. (Pubitemid 34211569)
96. Koga Y, Akita Y, Nishioka J, et al. L-Arginine improves the symptoms of stroke like episodes in MELAS. Neurology. 2005;64:710-2. (Pubitemid 40261903)
97. Koga Y, Povalko N, Nishioka J, et al. Biochim Biophys Acta. 1820;2012:608-14.